Who Paid My Doc
John Burke
Hematology & Oncology Aurora, CO Medical Doctor
NPI 1801871215 CMS profile 81413
1700 S Potomac St, Aurora, CO 80012
General payments
$320,697
Research payments
$44,680
Ownership & investment interest
$0
Research they led as principal investigator
$25,089,343
Through program year 2025, John Burke of Aurora, CO is reported in the CMS Open Payments database as having received $320,697 across 246 general payments and $44,680 in research payments paid to them. Separately, studies naming them as principal investigator received $25,089,343 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $49,602 | 32 | |
| 2025 | Research | $13,309 | 14 | |
| 2024 | General | $37,693 | 27 | |
| 2024 | Research | $13,985 | 13 | |
| 2023 | General | $36,382 | 46 | |
| 2022 | General | $38,063 | 25 | |
| 2022 | Research | $2,026 | 1 | |
| 2021 | General | $60,021 | 49 | |
| 2021 | Research | $1,425 | 2 | |
| 2020 | General | $56,000 | 25 | |
| 2020 | Research | $13,934 | 5 | |
| 2019 | General | $42,937 | 42 |
Beside peers
- John Burke
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to John Burke were reported at $49,602. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | John Burke | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $42,937 | $529 | $121–$2,516 | $163 |
| 2020 | $56,000 | $339 | $82–$2,213 | $114 |
| 2021 | $60,021 | $263 | $49–$1,965 | $132 |
| 2022 | $38,063 | $416 | $103–$2,395 | $149 |
| 2023 | $36,382 | $542 | $125–$2,646 | $160 |
| 2024 | $37,693 | $692 | $141–$3,008 | $164 |
| 2025 | $49,602 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 39 drugsPart D claims
1,901
Drug cost
$16,360,898
Branded share of claims
55.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Revlimid Lenalidomide | Brand | 418 | $8,985,702 | |
| Brukinsa Zanubrutinib | Brand | 164 | $2,349,341 | |
| Pomalyst Pomalidomide | Brand | 53 | $1,093,049 | |
| Venclexta Venetoclax | Brand | 62 | $864,115 | |
| Lenalidomide | Generic | 44 | $710,374 | |
| Jakafi Ruxolitinib Phosphate | Brand | 61 | $649,947 | |
| Imbruvica Ibrutinib | Brand | 43 | $599,277 | |
| Calquence Acalabrutinib Maleate | Brand | 20 | $299,498 | |
| Tasigna Nilotinib Hcl | Brand | 13 | $261,852 | |
| Ninlaro Ixazomib Citrate | Brand | 14 | $182,555 |
The 10 drugs with the highest cost, of 39 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 209 billing codesPaid by Medicare
$4,533,549
Medicare patients
946
Services billed
269,278
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 66% | |
| Arthritis | 46% | |
| Cancer | 33% | |
| Chronic kidney disease | 32% | |
| Ischemic heart disease | 28% | |
| Diabetes | 24% | |
| COPD | 22% | |
| Atrial fibrillation | 21% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, daratumumab, 10 mg and hyaluronidase-fihj J9144 | Office | 21 | 25,380 | $996,322 |
| Injection, pembrolizumab, 1 mg J9271 | Office | 13 | 7,200 | $319,668 |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg J1568 | Office | 32 | 8,220 | $302,697 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg Q5119 | Office | 17 | 3,758 | $60,915 |
| Injection, ferric derisomaltose, 10 mg J1437 | Office | 18 | 2,100 | $32,499 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg J2506 | Office | 15 | 480 | $23,240 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) J0881 | Office | 12 | 5,440 | $12,885 |
| Injection, aprepitant, 1 mg J0185 | Office | 11 | 3,380 | $4,516 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) Q0138 | Office | 11 | 13,260 | $3,369 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram Q5101 | Office | 17 | 11,400 | $2,777 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 16 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| ONIVYDE |
|
$3,418 | — | — |
| MONJUVI |
|
$3,080 | — | — |
| SOMATULINE DEPOT |
|
$1,958 | — | — |
| BRUKINSA |
|
$1,625 | 164 | — |
| KYMRIAH |
|
$1,313 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 16 in the dashboard with a free accountRecords
281 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in Colorado
Amy Schmidt
Hematology & Oncology · Denver, CO
Yousuf Gaffar
Hematology & Oncology · Denver, CO
Manojkumar Bupathi
Hematology & Oncology · Littleton, CO
Steven Schuster
Hematology & Oncology · Fort Collins, CO
Douglas Reznick
Hematology & Oncology · Aurora, CO
Daniel Pollyea
Hematology & Oncology · Aurora, CO
Related records
Hematology & Oncology in Colorado
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Colorado
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.